Novartis’ remibrutinib wins two Phase 3 multiple sclerosis trials as BTK strategy gets a crucial lift
Remibrutinib beat teriflunomide on relapse rates and every key secondary endpoint across the Phase 3 REMODEL studies, while avoiding the liver-safety signal that has complicated development of other BTK inhibitors.